Table 1.
Key baseline characteristics from each CVOT
| Trial/year of publication | Study drug/follow-up (y) | Participants (n) | Mean age years | Baseline HbA1c | Prior CVD (%) | Study funder |
|---|---|---|---|---|---|---|
| DPP-4i | ||||||
| SAVOR-TIMI 53 | Saxagliptin | 16,492 | 65.0 | 8.0% | 78.6 | AstraZeneca |
| 2013 | 2.1 | 64 mmol | Bristol-Myers | |||
| EXAMINE | Alogliptin | 5380 | 61.0 | 8.0% | 100 | Takeda |
| 2013 | 1.5 | 64 mmol | ||||
| TECOS | Sitagliptin | 14,6671 | 66.0 | 7.3% | 74 | Merck Sharp & |
| 2015 | 2.8 | 56 mmol | Dohme | |||
| CARMELINA | Linagliptin | 6979 | 65.9 | 7.9% | 100 | Boehringer |
| 2018 | 2.2 | 63 mmol | Ingelheim | |||
| GLP-1RA | ||||||
| ELIXA | Lixisenatide | 6068 | 60 | 7.7% | 100 | Sanofi |
| 2015 | 2.1 | 61 mmol | ||||
| LEADER | Liraglutide | 9340 | 64.3 | 8.7% | 72.4 | Novo-Nordisk |
| 2016 | 3.8 | 72 mmol | ||||
| SUSTAIN-6 | Semaglutide | 3297 | 64.6 | 8.7% | 83.0 | Novo-Nordisk |
| 2016 | 3.1 | 72 mmol | ||||
| EXSCEL | Exenatide OW | 14,752 | 62.0 | 8.0% | 73.1 | Amylin Pharma- |
| 2017 | 3.2 | 64 mmol | ceuticals | |||
| HARMONY | Albiglutide | 9463 | 64.0 | 8.7% | 100 | GlaxoSmithKline |
| 2018 | 1.6 | 72 mmol | ||||
| REWIND | Dulaglutide | 9901 | 66.2 | 7.2% | 31.4 | Boehringer/Lilly |
| 2019 | 5.4 | 55 mmol | ||||
| PIONEER 6 | Semaglutide O | 3183 | 66.0 | 8.2% | 84.7 | Novo-Nordisk |
| 2019 | 1.3 | 66 mmol | ||||
| AMPLITUDE-0 | Efpeglenatide | 4076 | 64.5 | 8.9% | 89.6 | Sanofi |
| 2021 | 1.8 | 74 mmol | ||||
| SGLT-2i | ||||||
| EMPA-REG | Empagliflozin | 7021 | 63.2 | 8.1% | 100 | Boehringer/Lilly |
| 2015 | 3.1 | 65 mmol | ||||
| CANVAS | Canagliflozin | 10,142 | 63.2 | 8.2% | 72.2 | Janssen |
| 2017 | 2.4 | 66 mmol | ||||
| DECLARE | Dapagliflozin | 17,160 | 63.8 | 8.3% | 40.6 | AstraZeneca |
| 2017 | 4.2 | 67 mmol | ||||
| CREDENCE | Canagliflozin | 4401 | 63.0 | 8.3% | 50.4 | Janssen |
| 2019 | 2.6 | 67 mmol | ||||
| VERTIS-CV | Ertugliflozin | 8246 | 64.4 | 8.2% | 100 | Merck Sharp & |
| 2020 | 3.0 | 66 mmol | Dohme | |||
| SCORED | Sotagliflozin | 10,584 | 69.0 | 8.3% | 48.6 | Sanofi/Lexicon |
| 2021 | 1.4 | 67 mmol | Pharmaceuticals | |||
OW once weekly, O oral